Open Access Articles- Top Results for Amrubicin


Systematic (IUPAC) name
Clinical data
AHFS/ International Drug Names
  • (Prescription only)
110267-81-7 7pxN
PubChem CID 178149
ChemSpider 2299344 7pxY
UNII 93N13LB4Z2 7pxY
KEGG D08854 7pxY
ChEMBL CHEMBL1186894 7pxN
Chemical data
Formula C25H25NO9
483.46 g/mol
 14pxN (what is this?)  (verify)

Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.[1] It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed.[2]

Amrubicin acts by inhibiting topoisomerase II, and has been compared in clinical trials with topotecan, a Topoisomerase I inhibitor.[3] [4]

It has also been studied for the treatment of bladder carcinoma[5] and gastric cancer.[6]


  1. ^ Ueoka H, Ohnoshi T, Kimura I (November 1992). "[New anthracycline analogues in the treatment of lung cancer]". Gan To Kagaku Ryoho (in Japanese) 19 (13): 2146–9. PMID 1332624. 
  2. ^ Sumitomo Pharmaceuticals Co., Ltd. (2003). "CALSED for Injection (English)" (PDF). Retrieved 2008-08-17. [dead link]
  3. ^ Celgene Corporation (2008). "Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer". Retrieved 2009-07-10. 
  4. ^ Medical News Today (2007). "Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer". Retrieved 2009-07-10. 
  5. ^ Ohmori H, Tsushima T, Kobashi K (April 1996). "[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]". Gan To Kagaku Ryoho (in Japanese) 23 (5): 601–6. PMID 8678519. 
  6. ^ Tsushima K, Sakata Y, Munakata A et al. (June 1991). "[A phase II study of SM-5887 for advanced gastric cancer]". Gan To Kagaku Ryoho (in Japanese) 18 (7): 1151–4. PMID 1647150. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.